Impact of hookworm infection and deworming on anaemia in non-pregnant populations: a systematic review.
OBJECTIVE
To summarise age- and intensity-stratified associations between human hookworm infection and anaemia and to quantify the impact of treatment with the benzimidazoles, albendazole and mebendazole, on haemoglobin and anaemia in non-pregnant populations.


METHODS
Electronic databases (MEDLINE, EMBASE, PubMed) were searched for relevant studies published between 1980 and 2009, regardless of language, and researchers contacted about potential data. Haemoglobin concentration (Hb) was compared between uninfected individuals and individuals harbouring hookworm infections of different intensities, expressed as standardised mean differences (SMD) and 95% confidence intervals (CI). Meta-analysis of randomised control trials (RCTs) investigated the impact of treatment on Hb and anaemia.


RESULTS
Twenty-three cross-sectional studies, six pre- and post-intervention studies and 14 trials were included. Among cross-sectional studies, moderate- and heavy-intensity hookworm infections were associated with lower Hb in school-aged children, while all levels of infection intensity were associated with lower Hb in adults. Among RCTs using albendazole, impact of treatment corresponded to a 1.89 g/l increase (95%CI: 0.13-3.63) in mean Hb while mebendazole had no impact. There was a positive impact of 2.37 g/l (95%CI: 1.33-3.50) on mean Hb when albendazole was co-administered with praziquantel, but no apparent additional benefit of treatment with benzimidazoles combined with iron supplementation. The mean impact of treatment with benzimidazoles alone on moderate anaemia was small (relative risk (RR) 0.87) with a larger effect when combined with praziquantel (RR 0.61).


CONCLUSIONS
Anaemia is most strongly associated with moderate and heavy hookworm infection. The impact of anthelmintic treatment is greatest when albendazole is co-administered with praziquantel.
Smith
Jennifer L
JL
Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, UK. jennifer.l.smith@lshtm.ac.uk
Brooker
Simon
S
D000293:Adolescent; D000328:Adult; D000368:Aged; D015766:Albendazole / Q000627:therapeutic use; D000740:Anemia / Q000097:blood / Q000469:parasitology*; D000871:Anthelmintics / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D005260:Female; D006454:Hemoglobins / Q000378:metabolism; D006725:Hookworm Infections / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D007223:Infant; D008463:Mebendazole / Q000627:therapeutic use; D008875:Middle Aged; D011223:Praziquantel / Q000627:therapeutic use; D011247:Pregnancy; D012107:Research Design
D000871:Anthelmintics; D006454:Hemoglobins; D011223:Praziquantel; D008463:Mebendazole; D015766:Albendazole